1111 related articles for article (PubMed ID: 29723096)
1. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.
Molenaar RJ; Sidana S; Radivoyevitch T; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
J Clin Oncol; 2018 Jun; 36(18):1889-1892. PubMed ID: 29723096
[No Abstract] [Full Text] [Related]
2. Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al.
Meyer RM
J Clin Oncol; 2017 Aug; 35(24):2854-2855. PubMed ID: 28682688
[No Abstract] [Full Text] [Related]
3. Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al.
André MPE; Federico M; Fortpied C; Girinsky T; Meignan M; Raemaekers J
J Clin Oncol; 2017 Aug; 35(24):2853-2854. PubMed ID: 28682682
[No Abstract] [Full Text] [Related]
4. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
Lichtenstein M
J Clin Oncol; 2018 Jun; 36(18):1887. PubMed ID: 29723090
[No Abstract] [Full Text] [Related]
5. Selective Focus on Rare Hematologic Malignancies Misleads Risk-Benefit Assessment of Radioiodine Therapy of Thyroid Cancer.
Doss M
J Clin Oncol; 2018 Jun; 36(18):1883-1884. PubMed ID: 29723093
[No Abstract] [Full Text] [Related]
6. Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms.
Tulchinsky M; Baum RP; Bennet KG; Freeman LM; Jong I; Kairemo K; Marcus CS; Moadel RM; Suman P
J Clin Oncol; 2018 Jun; 36(18):1887-1888. PubMed ID: 29723091
[No Abstract] [Full Text] [Related]
7. Concerns About the Risk of Myeloid Malignancies After Radioiodine Therapy in Thyroid Cancer.
Sollini M; Chiti A
J Clin Oncol; 2018 Jun; 36(18):1885-1886. PubMed ID: 29723098
[No Abstract] [Full Text] [Related]
8. Re: "A Follow-Up Strategy for Patients with Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma" by Jeon et al. (Thyroid 2018;28:187-192).
Rosario PW
Thyroid; 2018 Apr; 28(4):547-548. PubMed ID: 29583109
[No Abstract] [Full Text] [Related]
9. Response to Tulchinsky and Avram re: "Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 Millicurie Radioiodine".
Mujammami M; Tamilia M
Thyroid; 2017 Apr; 27(4):592. PubMed ID: 28178890
[No Abstract] [Full Text] [Related]
10. Reply to the Letter to the Editor by Sollini M et al.
Pacini F; Elisei R; Fugazzola L; Ferdeghini M; Mariotti S; Pellegriti G
J Endocrinol Invest; 2016 Apr; 39(4):487-8. PubMed ID: 26940215
[No Abstract] [Full Text] [Related]
11. Reply to E. Avisar, H. Kuerer, L. Livi et al, and E. Hindié et al.
Thorsen LB; Offersen BV; Overgaard J
J Clin Oncol; 2016 Aug; 34(22):2674-5. PubMed ID: 27217464
[No Abstract] [Full Text] [Related]
12. Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning.
Hindié E; Récher C; Zerdoud S; Leenhardt L; Avram AM
J Clin Oncol; 2018 Jun; 36(18):1881-1882. PubMed ID: 29723097
[No Abstract] [Full Text] [Related]
13. Reply to Y. Lu et al and E. Hindié et al.
Thorsen LBJ; Offersen BV
J Clin Oncol; 2022 Nov; 40(31):3670-3671. PubMed ID: 35787109
[No Abstract] [Full Text] [Related]
14. Reply to E. Hindié et al.
Connolly RM; Huang CY; Stearns V; Wahl RL
J Clin Oncol; 2019 Aug; 37(23):2092-2093. PubMed ID: 31251693
[No Abstract] [Full Text] [Related]
15. Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
Kolesar JM; Liu G
J Clin Oncol; 2018 Oct; 36(30):3065-3066. PubMed ID: 30188791
[No Abstract] [Full Text] [Related]
16. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid.
SEIDLIN SM; MARINELLI LD; OSHRY E
J Am Med Assoc; 1946 Dec; 132(14):838-47. PubMed ID: 20274882
[No Abstract] [Full Text] [Related]
17. Response to the Letter by Katiman E., et al.
Ruel E; Thomas S; Roman S; Sosa JA;
J Clin Endocrinol Metab; 2015 Jun; 100(6):L43-4. PubMed ID: 26047079
[No Abstract] [Full Text] [Related]
18. Inconclusive Analysis of the Connection Between Secondary Hematologic Malignancies and Radioiodine Treatment.
Kreissl MC; Grande E
J Clin Oncol; 2018 Jun; 36(18):1882-1883. PubMed ID: 29723089
[No Abstract] [Full Text] [Related]
19. Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Dudley JT; Leeper NJ; Shah NH
J Clin Oncol; 2016 Aug; 34(23):2804-5. PubMed ID: 27298415
[No Abstract] [Full Text] [Related]
20. Re: "Dynamic Risk Stratification for Predicting Recurrence in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy" by Park et al.: (Thyroid 2017;27:524-530).
Ayubi E; Sullman MJM; Safiri S
Thyroid; 2017 Dec; 27(12):1582. PubMed ID: 28967327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
